Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Teleflex (TFX), Sanofi (SNYNF) and Neurocrine (NBIX).
Teleflex (TFX)
Needham analyst Michael Matson maintained a Buy rating on Teleflex today and set a price target of $445.00. The company’s shares closed last Thursday at $398.66, close to its 52-week high of $414.72.
According to TipRanks.com, Matson is a 5-star analyst with an average return of 15.4% and a 69.1% success rate. Matson covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Zimmer Biomet Holdings, and Cardiovascular Systems.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Teleflex with a $450.75 average price target, implying a 15.6% upside from current levels. In a report issued on January 27, JMP Securities also maintained a Buy rating on the stock with a $440.00 price target.
See today’s analyst top recommended stocks >>
Sanofi (SNYNF)
Jefferies analyst Peter Welford maintained a Buy rating on Sanofi today and set a price target of EUR110.00. The company’s shares closed last Thursday at $94.28.
Welford has an average return of 7.1% when recommending Sanofi.
According to TipRanks.com, Welford is ranked #529 out of 7271 analysts.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Sanofi with a $116.45 average price target, implying a 23.5% upside from current levels. In a report issued on January 26, J.P. Morgan also maintained a Buy rating on the stock with a EUR93.00 price target.
Neurocrine (NBIX)
In a report released today, Joseph Stringer from Needham maintained a Hold rating on Neurocrine. The company’s shares closed last Thursday at $114.55.
According to TipRanks.com, Stringer is a 3-star analyst with an average return of 23.5% and a 66.7% success rate. Stringer covers the Healthcare sector, focusing on stocks such as Apellis Pharmaceuticals, Annexon Biosciences, and Stoke Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Neurocrine with a $123.79 average price target, a 9.4% upside from current levels. In a report issued on February 1, Mizuho Securities also maintained a Hold rating on the stock with a $117.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
